These molecular modifications significantly increase the difficulty of accurate GLP-1 Biosimilar Characterization, especially during impurity profiling, stability studies, and biosimilar comparability studies
While the FDA declared the semaglutide shortage resolved in February 2025, 503A pharmacies like Belmar can still compound semaglutide for patients with documented medical needs that cannot be met by commercially available products
One study found no significant increase in NAION risk with semaglutide compared to other agents when using broad diagnostic criteria
That is not something that needs to be done to safely take these medications." Too often, she says, these telehealth companies seem to be prioritizing gatekeeping the medications and keeping costs down over the needs of patients.
Second, dose matters more than most people realize
A lab test can show if you are low